NEW YORK (GenomeWeb News) — Transgenomic yesterday said third-quarter revenues rose 6 percent as R&D spending increased 23 percent and net loss widened by nearly 25 percent.
 
Total receipts for the three months ended Sept. 30 rose to $5.2 million from $4.9 million year over year.
 
Transgenomic CEO Craig Tuttle said in a statement that the increase in revenue “reflects continued growth in our molecular diagnostics reference lab and Pharmaceutical Services businesses.”
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.